JPS6028961A - N-1-adamantylmaleimide and its preparation - Google Patents

N-1-adamantylmaleimide and its preparation

Info

Publication number
JPS6028961A
JPS6028961A JP13557783A JP13557783A JPS6028961A JP S6028961 A JPS6028961 A JP S6028961A JP 13557783 A JP13557783 A JP 13557783A JP 13557783 A JP13557783 A JP 13557783A JP S6028961 A JPS6028961 A JP S6028961A
Authority
JP
Japan
Prior art keywords
formula
acid
adamantylmaleimide
agent
maleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP13557783A
Other languages
Japanese (ja)
Inventor
Yoshitaro Takatori
高取 D太郎
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to JP13557783A priority Critical patent/JPS6028961A/en
Publication of JPS6028961A publication Critical patent/JPS6028961A/en
Pending legal-status Critical Current

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)

Abstract

NEW MATERIAL:N-1-Adamantylmaleimide of formula I . USE:Carcinostatic agent, antivirus agent. PREPARATION:The reaction between equimolar amounts of maleic acid or its anhydride of formula II and amandazine (=1-aminoadamantane) of formula IIIis carried out in a solvent such as dioxane under heating to form N-1-adamantyl- aminomaleic acid almost quantitatively, then the product is heated with a few moles, per mole of the maleic acid, of a condensation agent such as polyphosphoric acid, acetic anhydride or anhydrous sodium acetate for a relatively short time to give the compound of formula I in good yield.

Description

【発明の詳細な説明】 本発明は無水マレイン酸あるいはマレイン酸とアマンタ
ジン(1−アミノアダマンタン) IJII縮合させ、
中間体N−1−アダマンチルアミノマレイン酸を製造し
、この中間体を脱水縮合剤の存在下で加熱閉環させて目
的物N−1−アダマンチルマレイミドを得ることを特徴
とするN−1−アダマンチルマレイミドの製法にかかる
。 其の目的とする所は、制癌剤、抗ウィルス剤として
有用なる新化合物を容易に製造し、臨床上の治療薬物と
して提供するにある。
Detailed Description of the Invention The present invention involves the condensation of maleic anhydride or maleic acid with amantadine (1-aminoadamantane) IJII,
N-1-adamantylmaleimide, which is characterized in that the intermediate N-1-adamantylaminomaleic acid is produced, and this intermediate is ring-closed by heating in the presence of a dehydration condensing agent to obtain the target product N-1-adamantylmaleimide. It takes a manufacturing method. The purpose is to easily produce new compounds useful as anticancer agents and antiviral agents, and to provide them as clinical therapeutic drugs.

本発明者は研究の結果N−1−アダマンチルマレイミド
が文・献未記載・の新化合物であり、強い制癌、抗つイ
/I/ス作用を有することを発見した。
As a result of research, the present inventor discovered that N-1-adamantylmaleimide is a new compound that has not been described in any literature or references, and has strong anticancer and anti-inflammatory and anti-inflammatory effects.

本化合物の合成径路は下記の工程で示される。The synthetic route for this compound is shown in the following steps.

第2工程 第1工程は当量の無水マレイン酸またはマレイン[rf
T販アマンタジン(1−アミノアダマンタン)を混和し
、適当な溶媒中で加熱、反応させることにより容易に進
行し、殆んど定量的に中間体−1るN−1−アダマンチ
ルアミノマレイン酸ヲ得ることができる。 適当な溶媒
としてはジオキサン、テトラヒドロフランなどを挙げ得
る。 この中間体はエタノールより再結晶することがで
き、融点2030(分解)の白色結晶である。 その元
素分析値は分子式014H1903N に対し下記のよ
うによく一致した。
Second step The first step is an equivalent amount of maleic anhydride or maleic [rf
By mixing T-sold amantadine (1-aminoadamantane) and heating and reacting in a suitable solvent, the reaction proceeds easily and yields intermediate-1, N-1-adamantylaminomaleic acid, almost quantitatively. be able to. Suitable solvents may include dioxane, tetrahydrofuran, and the like. This intermediate can be recrystallized from ethanol and is a white crystal with a melting point of 2030 (decomposed). The elemental analysis values were in good agreement with the molecular formula 014H1903N as shown below.

計算値−C乙7.t7% 実験値 C乙7.3g%H7
,乙3呪 H7J/% N 3.62% N 3.6!r% 第2工程に用いられる縮合剤としてポリ燐酸や無水酢酸
・酢酸ソーダ無水物の混合物などを挙げることができる
。 第1工程で得られた中間体N−1−アダマンチルア
ミノマレイン酸/モpに対し、これら縮合剤の数モルを
混和し、比較的短時間加熱、反応させることにょシ目的
物であるN−1−アダマンチル/マレイミドを好収量に
得ることができる。 本化合物は希エタノールから再結
晶することにより精製でき、精製品は融点//乙〜//
gの白色に淡黄色結晶で、其の赤外スペクトルチャート
は第7図の如くである。 また其の元素分析値は分子式
(314H1702N に対し下記のようによく一致し
た。
Calculated value-C7. t7% Experimental value C7.3g%H7
, Otsu 3 Curse H7J/% N 3.62% N 3.6! r% Examples of the condensing agent used in the second step include polyphosphoric acid and a mixture of acetic anhydride and sodium acetate anhydride. Several moles of these condensing agents are mixed with the intermediate N-1-adamantylaminomaleic acid/mop obtained in the first step, and the desired product N- 1-Adamantyl/maleimide can be obtained in good yield. This compound can be purified by recrystallization from dilute ethanol, and the purified product has a melting point of
It is a white to pale yellow crystal of g, and its infrared spectrum chart is as shown in Fig. 7. Moreover, its elemental analysis values were in good agreement with the molecular formula (314H1702N) as shown below.

計算[C72,70% 実験値C72,1,O%H7,
lI/% H7,lIO% N 乙、06% N 乙、77% 値は腹腔内投与で230mg/に、gであった。 マウ
ス移植癌に対する制癌実験でP3Kg、L/210に有
効なほか、特に腹水乳癌MM2、ルイス肺癌によ〈奏効
し、治癒例を多く見た。 またin vitr。
Calculation [C72,70% Experimental value C72,1, O%H7,
lI/% H7, lIO% N Otsu, 06% N Otsu, 77% The value was 230 mg/g by intraperitoneal administration. In anticancer experiments on transplanted cancers in mice, it was effective against P3Kg and L/210, and was particularly effective against ascites breast cancer MM2 and Lewis lung cancer, with many cured cases. Also in vitr.

実験でHerpes 8implexの強い発育抑制を
認めた。
In experiments, strong inhibition of the growth of Herpes 8 complex was observed.

反応実施例 1、N−1−アダマンチルアミノマレイン酸の製法(1
) 無水マレイン酸2り、lAgC0,3モlし)トア
マンタジンl15.3 ’g < o、3モル)′f、
よく混和し、so。
Reaction Example 1, Process for producing N-1-adamantylaminomaleic acid (1
) 2 maleic anhydride, lAgC0.3 mol) toamantadine l15.3'g < o, 3 mol)'f,
Mix well and so.

m!のジオキサンを加え、水浴上に加熱すれば結晶は全
溶する。 60分間加熱、還流を続ける。
m! Add dioxane and heat on a water bath to completely dissolve the crystals. Continue heating and refluxing for 60 minutes.

放冷後析出する結晶を吸炉、乾燥する。 白色結晶とし
て中間体のN−1−アダマンチルアミノマレイン酸をご
乙、夕g(理論量の2g%)得た。
After cooling, the precipitated crystals are dried in a suction furnace. The intermediate N-1-adamantylaminomaleic acid was obtained as white crystals (2 g% of the theoretical amount).

(2) マレイン酸33gC0,3モル)トアマンタジ
ンll!;、3g (0−3モw)を500m、l/の
ジオキサン中で60分間加熱、還流することによりN−
1−アダランチlレアミノマレイン酸f l−3,0g
(理論量のり7%)を得た。
(2) Maleic acid 33gC0.3 mol) Toamantadine ll! N-
1-adalanthi l rare amino maleic acid f l-3,0g
(7% of theoretical amount) was obtained.

2、N−1−アダマンチルマレイミドの製法(1)N−
1−アダマンチルアミノマレイン酸乙7゜3gC0−3
モlV)にポリリン酸230gを加え、液温2000の
油浴中に30分加熱後放冷し、内容物を大量の氷水中に
あける。 析出物を吸枦、水洗、乾燥する。 粗結晶の
収量3 、LA g (理論量の57%)これを50%
エタノ−Iしから再結晶すれば融点//乙〜//g0の
白色〜淡黄色結晶が得られる。
2. Process for producing N-1-adamantylmaleimide (1) N-
1-adamantylaminomaleic acid Otsu 7゜3gC0-3
Add 230 g of polyphosphoric acid to mol V), heat for 30 minutes in an oil bath at a liquid temperature of 2000, allow to cool, and pour the contents into a large amount of ice water. Suction the precipitate, wash with water, and dry. Yield of crude crystals 3, LA g (57% of theoretical amount) This was reduced to 50%
Recrystallization from ethanol-I yields white to pale yellow crystals with a melting point of //O~//g0.

(2)N−1−アダマンチルマレイン酸乙り、3g<0
.3モル)に無水酢酸乙o m7 、無水酢酸ナトリウ
ム20gの・混合物を加え、沸騰水浴上60分間加熱す
る。 冷接内容物を大量の氷水中にあける。 析出物を
吸沖、水洗、乾燥する。
(2) N-1-adamantylmaleic acid, 3g<0
.. A mixture of 3 mol of acetic anhydride and 20 g of anhydrous sodium acetate was added to the mixture and heated on a boiling water bath for 60 minutes. Pour the cold contents into a large amount of ice water. Suck up the precipitate, wash with water, and dry.

粗結晶の収量3 o、s g (理論量の17g%)。Yield of crude crystals: 3 o, s g (17 g% of theory).

【図面の簡単な説明】[Brief explanation of drawings]

第1図は、赤外スペクトルチャートである。 特許出願人 高 取 告太部 FIG. 1 is an infrared spectrum chart. patent applicant Takatori Kotabu

Claims (1)

【特許請求の範囲】 1、下記構造式で表わされるN−1−アダマンチルマレ
イミド。 N′ 2、下記構造式で表わされるN−1−アダマンチルマレ
イミドの製法。
[Claims] 1. N-1-adamantylmaleimide represented by the following structural formula. N'2, a method for producing N-1-adamantylmaleimide represented by the following structural formula.
JP13557783A 1983-07-25 1983-07-25 N-1-adamantylmaleimide and its preparation Pending JPS6028961A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP13557783A JPS6028961A (en) 1983-07-25 1983-07-25 N-1-adamantylmaleimide and its preparation

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP13557783A JPS6028961A (en) 1983-07-25 1983-07-25 N-1-adamantylmaleimide and its preparation

Publications (1)

Publication Number Publication Date
JPS6028961A true JPS6028961A (en) 1985-02-14

Family

ID=15155063

Family Applications (1)

Application Number Title Priority Date Filing Date
JP13557783A Pending JPS6028961A (en) 1983-07-25 1983-07-25 N-1-adamantylmaleimide and its preparation

Country Status (1)

Country Link
JP (1) JPS6028961A (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002024692A1 (en) * 2000-09-20 2002-03-28 Karolinska Innovations Ab 1-azabicyclo[2.2.2]octan-3-one derivatives and maleimide derivatives and their use for treating cancer tumors

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002024692A1 (en) * 2000-09-20 2002-03-28 Karolinska Innovations Ab 1-azabicyclo[2.2.2]octan-3-one derivatives and maleimide derivatives and their use for treating cancer tumors

Similar Documents

Publication Publication Date Title
FI113765B (en) Process for the preparation of novel antiproliferative 5-substituted quinazoline compounds
WO2020239039A1 (en) Method for preparing tetrazine compounds and application thereof
CN103601762A (en) Ferrocene derivatives, preparation method and use thereof
JPS6033114B2 (en) 1,2-benzisoxazole derivative
JPH0150698B2 (en)
JPS6028961A (en) N-1-adamantylmaleimide and its preparation
JPS61291575A (en) Production of benzoxazines
ZA200306429B (en) Quinoline, isoquinoline and phthalazine derivatives as antagonists of the gonadotropin-releasing hormone.
JPS5973579A (en) Benzofuran or benzothiophene derivative, diuretic agent containing said compound as active constituent and preparation thereof
JPS63243074A (en) Novel derivatives of pyridine, manufacture and intermediate, use as drug and composition
JPH10502048A (en) Novel pharmaceutically active compounds which can be formed from 1,3,4,6,7,8-hexahydro-2H-pyrimido- (1,2-a) -pyrimidine
JPH06506703A (en) Improved method for producing 2-arylbenzimidazole-5-sulfonic acid
JPS62223173A (en) Pyridylaminophenol derivative and production thereof
McKee et al. 6-(and 7-)-Chloro-4-(1-diethylamino-4-pentylamino)-2-(p-methoxyphenyl)-quinazoline Dihydrochlorides
US4186201A (en) Methods of using 8(tetrazol-5-ylcarbamoyl)isoquinoline compounds
JPS6011913B2 (en) 1,8-naphthyridine derivative and its manufacturing method
KR810002003B1 (en) Process for preparing pyrido(2-1-b) quinazoline derivatives
US4259499A (en) Method for preparing 2-sulfochloride benzoates and the use of same in the preparation of saccharin
KR840002243B1 (en) Process for preparing quinazoline derivatives
Wolf et al. 2-Chloro-4-aminoquinazoline
JPS6110587A (en) 1-azaxanthone-3-carboxylic acid derivative and preparation thereof
JPS6154016B2 (en)
WO2023143491A1 (en) Synthesis method for 7,8-dihydro-2h-cyclopentapyrrolopyrazinone compound
JPS6338354B2 (en)
JPH02145572A (en) N-substituted amide